CANCER GENE THERAPY USING CYTOKINE AND CHEMOKINE GENES

• Mukaida Naofumi

  Division of Molecular Bioregulation, Cancer Research Institute Kanazawa University

抄録

Surgical or radiotherapy-mediated eradication of tumors gives the best opportunity for cure, if the tumor is restricted to the primary sites. Chemotherapy is employed for disseminated disease but frequently fails to give clinical benefit. Thus, with our ever expanding understanding of the regulatory mechanisms of cytokine- and/or chemokine-mediated immune reactions to tumor, these molecules have become good candidates for cancer therapy. Unfortunately, most cytokines and chemokines have very short half-lives and their systemic delivery of pharmacological doses frequently results in severe adverse effects. These circumstances prompted many investigators to evaluate the genetic delivery of cytokines and chemokines for the treatment of cancer. Here, current status of clinical and pre-clinical studies of cytokine and chemokines will be discussed, particularly focusing on those with clinical relevance.

収録刊行物

• Ａｎｎａｌｓ　ｏｆ　Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ　ａｎｄ　Ｔｈｅｒａｐｙ

  Ａｎｎａｌｓ　ｏｆ　Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ　ａｎｄ　Ｔｈｅｒａｐｙ 12 (1/2), 33-51, 2004

  日本癌病態治療研究会

キーワード

• Adenovirus
• CC chemokine
• granulocyte macrophage-colony stimulating factor
• interleukin-2
• interleukin-4
• interleukin-12
• interferon-α
• interferon-β
• interferon-γ
• interferon-inducible protein-10
• monokine inducible by interferon-γ
• macrophage-derived chemokine
• monocyte chemoattractant protein-1
• retrovirus
• secondary lymphoid tissue chemokine

詳細情報

• CRID: 1390001205190159360
• NII論文ID: 130000120347
• DOI: 10.4993/acrt.12.33
• ISSN: 18805469
• ISSN: 13446835
• Web Site: http://www.jstage.jst.go.jp/article/acrt/12/1+2/12_1+2_33/_pdf
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可